|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study显示文摘AIM To make efficacy and safety comparison of telbivudineraodmap and tenofovir-roadmap in hepatitis B e antigen(HBe Ag)-negative chronic hepatitis B(CHB) patients.METHODS This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBe Ag-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up to 24 wk and, depending on virologic response, continued the same therapy or received addon therapy up to 104 wk. Eligible patients received an additional 52 wk of treatment in the extension period(i.e., up to 156 wk). Patients who developed virologic breakthrough(VB) while on monotherapy also received add-on therapy. The primary efficacy endpoint was the rate of patients achieving hepatitis B virus(HBV) DNA < 300 copies/m L at week 52. Secondary efficacy endpoints included the rates of HBV DNA < 300 and < 169 copies/m L, HBV DNA change from baseline, alanine aminotransferase normalisation, hepatitis B surface antigen(HBs Ag) loss, HBs Ag seroconversion, VB, and emergence of resistance at various timepoints throughout the study. Safety and estimated glomerular filtration rate(e GFR) were also analysed.RESULTS A total of 241 patients were randomised. Non-inferiority of telbivudine arm to tenofovir arm was demonstrated at week 52(± 7 d window), with over 91% of patients in each treatment arm achieving HBV DNA level < 300 copies/m L. Both arms were similar in terms of key secondary efficacy variables at weeks 104 and 156. The percentage of patients achieving HBV DNA < 300 copies/m L remained high and was similar in the telbivudine and tenofovir arms at both weeks 104 and 156. Over 82% of patients in both arms achieved alanine aminotransferase normalisation at week 52, and this percentage remained high at weeks 104 and 156. Telbivudine treatment progressively reduced serum HBs Ag levels from baseline while no change was reported in quantitative HBs Ag during therapy with tenofovir. Both treaments showed acceptable safety profiles. The telbivudine arm showed e GFR improvement unlike the tenofovir arm.CONCLUSION Efficacy was shown for both telbivudine-roadmap and tenofovir-roadmap regimens in HBe Ag-negative CHB patients over 156 wk. Telbivudine arm was associated with renal improvement. | Zahari Krastev Diana Petrova Iskren Kotzev Mustafa Kemal Celen Meryl Mendelson Richa Chandra Priti Pandey Kamal Hamed | 2016 | World Journal of Hepatology2016，8，32： | 9 |
| 2 | Asset pricing and the bid-ask spread 显示文摘 | Amihud Yakov and Haim Mendelson | 1986 | Journal of Financial Economics1986，17，： | 2 |
| 3 | Vascular complications of pancreatitis 显示文摘 | Mendelson RM Anderson J Marshall M | 2005 | ANZJ Surg2005，75，12： | 1 |
| 4 | Fatal and near-fatal anaphylactic reactions to food in children and adolescents显示文摘 | Sampson HA Mendelson L Rosen JP | 1992 | N Engl J Med1992，327，6： | 1 |
| 5 | Bronchogeniccyst with high CT numbers显示文摘 | Mendelson DS Rose JS Etremidis SC | 1983 | AJR1983，140，： | 1 |
| 6 | High resolution computed tomographyin idiopathic interstitial pneumonias 显示文摘 | Argiriadi PA Mendelson DS | 2009 | Mt Sinai J Med2009，76，1： | 1 |
| 7 | The aspiration of stomach contents into the lungs during obstetric anesthesia显示文摘 | Mendelson CI | 1946 | Am J Obstet Gynecol1946，52，： | 1 |
| 8 | Effects of time of night andsleep stage on perception of sleep in subjectswith sleep state misperception 显示文摘 | Mendelson WB | 1998 | Cochrane Central Register Control TrialsPsychobiol1998，26，1： | 1 |
| 9 | Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors显示文摘 | Gordon MS Sweeney CS Mendelson DS | 2010 | Clin Cancer Res2010，16，2： | 1 |
| 10 | A drug use evaluation of selected opioid and nonopioid analgesics in the nursing facility setting显示文摘 | Galer BS Mendelson MA | 2000 | J Am Geriatr Soc2000，48，4： | 1 |
| 11 | Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types land 2 显示文摘 | Aboudy Y Mendelson E Shalit L et M | 1994 | Int J Pept Protein Res1994，43，6： | 1 |
| 12 | A review of the evidence for the efficacy and safety of trazodone in insomnia显示文摘 | Mendelson WB | 2005 | J Clin Psychiatry2005，66，4： | 1 |
| 13 | Asset Pricing and The Bid-Ask Spread显示文摘 | Amihud Y Mendelson H | 1986 | Journal of Financial Economics1986，，17： | 1 |
| 14 | Mi- crobiological response to Linezolid vs Vancomycin in venti- lator- associated pneumonia due to Methicillin -resistant Staphylococcus aureus 显示文摘 | Wunderink RG Mendelson MH Somero MS | 2008 | Chest2008，134，： | 1 |
| 15 | Asset Pricing and the Bid-Ask Spread 显示文摘 | Y Amihud & H Mendelson | 1986 | Journal of Financial Economics1986，，17： | 1 |
| 16 | Strain-specific mycobacterial lipids and the stimulation of protective immunity to tuberculosis显示文摘 | Mendelson M Walters S Smith I | 2005 | Tuberculosis2005，85，： | 1 |
| 17 | Asset pricing and bid-ask spread显示文摘 | Yakov Ahimud Hain Mendelson | 1986 | Journal of Financial economics1986，17，： | 1 |
| 18 | Expression of mTORsignaling pathway markers in prostate cancer progression显示文摘 | Kremer CL Klein RR Mendelson J | 2006 | Prostate2006，66，11： | 1 |
| 19 | Drug-induced hypogly cemia coma in 102 diabetes patients显示文摘 | Ben AH Nahachandan P Mendelson A | 1999 | Arch intern Med1999，159，3： | 1 |
| 20 | Liquidity,asset prices and financial policy显示文摘 | Yakov Ahimud Hain Mendelson | 1991 | Financial Analysis Journal1991，47，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员